Advertisement
Economy

Pharmaceutical Tariffs Are Forcing Drugmakers to Rethink Where They Build

A pill’s country of origin is rarely the country where it was made, and almost never the country where its profits are booked.

That gap has become expensive. A typical medicine starts as a chemical intermediate made in one country, becomes an active ingredient in a second, is pressed or filled into its final form in a third, and is packaged in a fourth. The intellectual property behind it often sits with a subsidiary in a low-tax jurisdiction. Every border crossing in that chain is a place where a tariff can attach, and the people who designed the chain optimized it for tax efficiency, regulatory approval and unit cost, not for trade conflict.

Washington’s push to bring drug production home has forced executives to ask whether that design still makes sense. The answer is more complicated than the political messaging suggests, because pharmaceutical manufacturing does not relocate like a furniture line or a textile mill. It moves slowly, expensively and only with the blessing of regulators.

Technicians working on a pharmaceutical production line inside a manufacturing facility
Photo by Lech Pierchała / Pexels

How the Supply Chain Got Its Shape

The modern drug supply chain was built around three forces: tax law, labor and specialization. Countries such as Ireland and Switzerland became manufacturing hubs for branded medicines in part because their corporate tax regimes made it sensible to hold patents and production there. India built a huge generics industry on chemistry talent and low operating costs. China became deeply embedded in the production of basic chemical building blocks that feed ingredient manufacturers around the world. None of this happened by accident, and none of it was arranged to dodge a tariff regime that did not exist when the plants were planned.

The tariff mechanics are what make the arrangement vulnerable. Duties are generally assessed on the declared value of goods crossing a border, which means the price a company assigns when one subsidiary sells to another carries real weight. A drugmaker that ships a finished product into the United States from a European plant faces a very different bill depending on how much of the value is attributed to the physical product and how much to the intellectual property that lives elsewhere. Tax and customs teams, who rarely had to coordinate before, now sit in the same meetings. Rearranging that paperwork is the fastest response available, and it is the least visible one.

Building a new plant is the slow answer. A facility that makes sterile injectables or biologic drugs requires specialized equipment, a trained workforce and a validation process before regulators will allow a single batch to reach patients. A company cannot simply declare a new site open because the tariff schedule changed. Construction, equipment qualification, inspection and the transfer of a manufacturing process from one site to another can take years. In the meantime, the realistic moves are building inventory ahead of tariff deadlines, shifting volume among plants a company already operates, and renegotiating contracts with outside manufacturers.

Stacked shipping containers at a port representing global trade in goods
Photo by Bernd von Darl / Pexels

Who Can Absorb the Hit

The pain is not evenly distributed. Makers of patented, high-priced brand-name drugs carry margins wide enough to absorb a duty for a while, or to spread the cost across a global portfolio. Generic manufacturers do not have that cushion. They compete on razor-thin prices, often in markets where a buyer will switch suppliers over a few cents, and a new tariff can turn a profitable product into a money-loser overnight. A company in that position does not reroute its supply chain. It stops making the product.

That is the risk that worries hospital pharmacists and health policy specialists more than any boardroom decision. When a low-margin sterile injectable becomes unprofitable, it tends to disappear quietly, and the shortages follow months later. Older generic drugs are the least glamorous part of the industry and the most widely used. A policy intended to strengthen domestic supply could, if it is applied bluntly, thin out the supply of the cheap staples that hospitals depend on every day. Exemptions and phase-ins can soften the blow, but each exemption also tells manufacturers that the rules may change again.

That uncertainty may be the biggest factor shaping corporate behavior. A manufacturing plant is a decade-long commitment, while a tariff can be raised, lowered, traded away or struck down within a single news cycle. Faced with that mismatch, drugmakers tend to hedge. Pledges of new American investment are easy to announce and politically useful, and they preserve goodwill with the administration. Actual construction decisions can be staged, with modular expansions at existing U.S. sites, second-source agreements for key ingredients and options on land or capacity that can be exercised if the policy proves durable. The headline number and the shovel-ready number are rarely the same.

Rows of sterile glass vials on a laboratory production line
Photo by Jess Loiterton / Pexels

The Part No Ribbon-Cutting Fixes

A tariff can be announced in an afternoon, but a sterile manufacturing line has to pass inspection before a single vial ships, and no trade negotiation can speed that part up.

Related Articles

Back to top button